Finally, an investigation of neuronal (NfL) and astrocyte damage (GFAP), myeloid activation (sCD163) and BBB permeability (MMP-9 and TIMP-1) was performed on the CSF samples of hospitalized COVID-19 patients with severe NS on hospital admission. This evidence concerns the gene CD163 and COVID-19.